



Medi-Cal Rx

Mass Adjustment for Impacted Paxlovid Renal Dose Claims with a Date of Service April 1, 2022, through January 17, 2024

September 6, 2024

Background

The purpose of this alert is to inform pharmacy providers that Medi-Cal Rx initiated a mass adjustment related to Paxlovid™ (nirmatrelvir and ritonavir tablets) renal dose claims with a date of service (DOS) on or after April 1, 2022, through January 17, 2024.

What Pharmacy Providers Need to Know

Medi-Cal Rx identified a claims processing issue affecting a select number of claims with a DOS on or after April 1, 2022, through January 17, 2024, for Paxlovid (nirmatrelvir and ritonavir tablets) renal dose claims with NDCs 00069110104 and 00069110120. For these claims, the Medi-Cal Rx reimbursement calculation used an incorrect ingredient cost which may have resulted in an incorrect pharmacy provider reimbursement. Medi-Cal Rx updated the claim reimbursement calculation for these NDCs on January 17, 2024, to correctly calculate the reimbursement for Paxlovid (nirmatrelvir and ritonavir tablets) renal dose claims per the Department of Health Care Services' (DHCS) policy.

Medi-Cal Rx has identified the impacted net paid claims and will be adjusting these claims on behalf of pharmacy providers which may result in an amount you owe DHCS or no net change to the amount you were already reimbursed.

Adjustments have been made for some of the impacted claims with a DOS on or after April 1, 2022, through January 17, 2024, and will appear on the September 20, 2024, remittance advice (RA). Adjustments for the remaining claims with a DOS on or after April 1, 2022, through January 17, 2024, will be processed by Medi-Cal Rx at a later date and a separate alert will be published when the next adjustment commences.

What Pharmacy Providers Need to Do

No action is required by pharmacy providers at this time.

Adjustments for some of the impacted claims submitted with a DOS on or after April 1, 2022, through January 17, 2024, will appear on the September 20, 2024 RA. On the RA, impacted pharmacy providers will see a reversal of the original claim and a new claim processed (same member, Rx number, DOS, NDC, etc.) to reflect the adjustment. Adjustments for the remaining claims with a DOS on or after April 1, 2022, through January 17, 2024, will be processed by Medi-Cal Rx at a later date and a separate alert will be published when the next adjustment commences.

Mass Adjustment for Impacted Paxlovid
Renal Dose Claims with a Date of Service
April 1, 2022, through January 17, 2024

09/06/2024

For more information about this and other mass adjustment activities, refer to the [Mass Adjustments](#) page located on the [Medi-Cal Rx Provider Portal](#). For additional assistance, pharmacy providers may send a secured email to MediCalRxEducationOutreach@primetherapeutics.com and include, if appropriate, any claim-specific information with the correspondence.

Contact Information

If you have any questions regarding the mass adjustment, call the Medi-Cal Rx Customer Service Center (CSC) at 1-800-977-2273, which is available 24 hours a day, 7 days a week, 365 days per year.

For other questions, email Medi-Cal Rx Education & Outreach at MediCalRxEducationOutreach@primetherapeutics.com.